452 related articles for article (PubMed ID: 15958626)
21. Centrosome hyperamplification predicts progression and tumor recurrence in bladder cancer.
Yamamoto Y; Matsuyama H; Furuya T; Oga A; Yoshihiro S; Okuda M; Kawauchi S; Sasaki K; Naito K
Clin Cancer Res; 2004 Oct; 10(19):6449-55. PubMed ID: 15475431
[TBL] [Abstract][Full Text] [Related]
22. Identification of gene expression patterns in superficial and invasive human bladder cancer.
Thykjaer T; Workman C; Kruhøffer M; Demtröder K; Wolf H; Andersen LD; Frederiksen CM; Knudsen S; Orntoft TF
Cancer Res; 2001 Mar; 61(6):2492-9. PubMed ID: 11289120
[TBL] [Abstract][Full Text] [Related]
23. Survivin expression in patients with non-muscle-invasive urothelial cell carcinoma of the bladder.
Karam JA; Lotan Y; Ashfaq R; Sagalowsky AI; Shariat SF
Urology; 2007 Sep; 70(3):482-6. PubMed ID: 17905101
[TBL] [Abstract][Full Text] [Related]
24. Molecular alterations associated with bladder cancer initiation and progression.
Cordon-Cardo C
Scand J Urol Nephrol Suppl; 2008 Sep; (218):154-65. PubMed ID: 18815930
[TBL] [Abstract][Full Text] [Related]
25. High-throughput tissue microarray analysis of COX2 expression in urinary bladder cancer.
Wild PJ; Kunz-Schughart LA; Stoehr R; Burger M; Blaszyk H; Simon R; Gasser T; Mihatsch M; Sauter G; Hartmann A
Int J Oncol; 2005 Aug; 27(2):385-91. PubMed ID: 16010419
[TBL] [Abstract][Full Text] [Related]
26. Chromosomal imbalances in noninvasive papillary bladder neoplasms (pTa).
Zhao J; Richter J; Wagner U; Roth B; Schraml P; Zellweger T; Ackermann D; Schmid U; Moch H; Mihatsch MJ; Gasser TC; Sauter G
Cancer Res; 1999 Sep; 59(18):4658-61. PubMed ID: 10493521
[TBL] [Abstract][Full Text] [Related]
27. [Molecular changes in development and progression of urothelial carcinoma].
Hartmann A
Verh Dtsch Ges Pathol; 2003; 87():172-84. PubMed ID: 16888910
[TBL] [Abstract][Full Text] [Related]
28. Association of TSC1/hamartin, 14-3-3sigma, and p27 expression with tumor outcomes in patients with pTa/pT1 urothelial bladder carcinoma.
Mhawech-Fauceglia P; Alvarez V; Fischer G; Beck A; Herrmann FR
Am J Clin Pathol; 2008 Jun; 129(6):918-23. PubMed ID: 18480009
[TBL] [Abstract][Full Text] [Related]
29. Gene expression profiling of differentiated thyroid neoplasms: diagnostic and clinical implications.
Chevillard S; Ugolin N; Vielh P; Ory K; Levalois C; Elliott D; Clayman GL; El-Naggar AK
Clin Cancer Res; 2004 Oct; 10(19):6586-97. PubMed ID: 15475448
[TBL] [Abstract][Full Text] [Related]
30. Identification and prognostic significance of an epithelial-mesenchymal transition expression profile in human bladder tumors.
Baumgart E; Cohen MS; Silva Neto B; Jacobs MA; Wotkowicz C; Rieger-Christ KM; Biolo A; Zeheb R; Loda M; Libertino JA; Summerhayes IC
Clin Cancer Res; 2007 Mar; 13(6):1685-94. PubMed ID: 17363521
[TBL] [Abstract][Full Text] [Related]
31. Value of multicolour fluorescence in situ hybridisation (UroVysion) in the differential diagnosis of flat urothelial lesions.
Schwarz S; Rechenmacher M; Filbeck T; Knuechel R; Blaszyk H; Hartmann A; Brockhoff G
J Clin Pathol; 2008 Mar; 61(3):272-7. PubMed ID: 17693577
[TBL] [Abstract][Full Text] [Related]
32. Role of activating fibroblast growth factor receptor 3 mutations in the development of bladder tumors.
Zieger K; Dyrskjøt L; Wiuf C; Jensen JL; Andersen CL; Jensen KM; Ørntoft TF
Clin Cancer Res; 2005 Nov; 11(21):7709-19. PubMed ID: 16278391
[TBL] [Abstract][Full Text] [Related]
33. Gene expression in the urinary bladder: a common carcinoma in situ gene expression signature exists disregarding histopathological classification.
Dyrskjøt L; Kruhøffer M; Thykjaer T; Marcussen N; Jensen JL; Møller K; Ørntoft TF
Cancer Res; 2004 Jun; 64(11):4040-8. PubMed ID: 15173019
[TBL] [Abstract][Full Text] [Related]
34. Does the expression of fascin-1 and tumor subclassification help to assess the risk of recurrence and progression in t1 urothelial urinary bladder carcinoma?
Soukup V; Babjuk M; Dusková J; Pesl M; Szakáczová M; Zámecník L; Dvorácek J
Urol Int; 2008; 80(4):413-8. PubMed ID: 18587253
[TBL] [Abstract][Full Text] [Related]
35. DNA microarray expression profiling of bladder cancer allows identification of noninvasive diagnostic markers.
Mengual L; Burset M; Ars E; Lozano JJ; Villavicencio H; Ribal MJ; Alcaraz A
J Urol; 2009 Aug; 182(2):741-8. PubMed ID: 19539325
[TBL] [Abstract][Full Text] [Related]
36. Frequent genetic alterations in flat urothelial hyperplasias and concomitant papillary bladder cancer as detected by CGH, LOH, and FISH analyses.
Obermann EC; Junker K; Stoehr R; Dietmaier W; Zaak D; Schubert J; Hofstaedter F; Knuechel R; Hartmann A
J Pathol; 2003 Jan; 199(1):50-7. PubMed ID: 12474226
[TBL] [Abstract][Full Text] [Related]
37. C-erbB-2 gene amplification: a molecular marker in recurrent bladder tumors?
Underwood M; Bartlett J; Reeves J; Gardiner DS; Scott R; Cooke T
Cancer Res; 1995 Jun; 55(11):2422-30. PubMed ID: 7757996
[TBL] [Abstract][Full Text] [Related]
38. Gene expression signatures predict outcome in non-muscle-invasive bladder carcinoma: a multicenter validation study.
Dyrskjøt L; Zieger K; Real FX; Malats N; Carrato A; Hurst C; Kotwal S; Knowles M; Malmström PU; de la Torre M; Wester K; Allory Y; Vordos D; Caillault A; Radvanyi F; Hein AM; Jensen JL; Jensen KM; Marcussen N; Orntoft TF
Clin Cancer Res; 2007 Jun; 13(12):3545-51. PubMed ID: 17575217
[TBL] [Abstract][Full Text] [Related]
39. Predicting favourable prognosis of urothelial carcinoma: gene expression and genome profiling.
van der Kwast TH; Bapat B
Curr Opin Urol; 2009 Sep; 19(5):516-21. PubMed ID: 19553819
[TBL] [Abstract][Full Text] [Related]
40. The frequency of hydronephrosis at initial diagnosis and its effect on recurrence and progression in patients with superficial bladder cancer.
Divrik RT; Sahin A; Altok M; Unlü N; Zorlu F
J Urol; 2007 Sep; 178(3 Pt 1):802-6; discussion 806. PubMed ID: 17632171
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
